Recently, the European Society of Medical Oncology (ESMO) published consensus statements for the management of EGFR-mutant NSCLC, highlighting the requirement for a distinct approach from diagnosis to management and from early to advanced stage [116]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.